Technology

Aarkstore announce a new report  “Innovations in Oncology Diagnostics: Technological advances, growth opportunities and future market outlook” through its vast collection of market research report. Despite public policy measures to prevent cancer, such as tobacco control and vaccination against HPV, cancer is sure to remain a significant public health problem throughout the 21st century. Indeed, the global demographic shift towards an ageing population and the spread of high tech modern medicine throughout the emerging economies of Asia and (maybe later) Africa, will expand the market for cancer diagnostics globally. Major developments are likely in both the IVD market and in imaging-based modalities, like computed tomography, with the emphasis being upon the personalized medicine approach, where demand will come from physicians, patients and payors – all of whom want more effective treatments and value for money. This report analyzes the latest innovations in oncology diagnostics and identifies the most exciting new technologies and trends, ranging from body imaging and cytology to molecular diagnostics and pharmacogenomics. The report also identifies the key challenges facing innovative diagnostics companies. Key Features of this report•Analysis the latest innovations in diagnostics imaging in the oncology sector, covering Magnetic Resonance Imaging (MRI), x-ray, Computed Tomography (CT), ultrasound, Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT) and Flow Cytometry.•Analyzes the latest innovations in molecular diagnostics and how they impact the diagnostics market. The report covers technology including fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), HPV testing, immunoassays & biomarkers, microarrays and comparative genomic hybridization (CGH).•Analyzes the latest innovations in pharmacogenomics and covers the major applications for familial cancer, breast cancer, colon cancer and lung cancer. Also, the report provides an overview of the regulatory and intellectual property environment for genetic-based tests.•Looks at the key commercial challenges for innovative diagnostics companies, including the impact of the recession, reimbursement, regulatory changes, pharmacoeconomics and the relationship between industry and academia.The report Includes in-depth case studies on the potential technologies available in core areas of un-met need such as ovarian cancer and colorectal cancer. Key benefits of this report•Understand the latest innovations in the oncology diagnostics market in the core areas – diagnostic imaging, molecular diagnostics and pharmacogenetics. This includes market information and an analysis of the scientific literature so as to identify what is really innovative.•Identify what the key areas of unmet need are in the oncology diagnostics market and understand which products have the greatest potential over the next decade.•Understand what the greatest challenges are for oncology diagnostics and what the best strategies are for coping with these obstacles. •Understand the competitive landscape and what companies are leading the way in terms of innovation, and what the latest partnerships regarding companion diagnostics.•Business Insights has identified five key areas of innovation in the diagnostics markets, use this to help guide company strategy.Key findings from this reportMolecular diagnostics and biomarkers are the key drivers of the oncology diagnostics market.Despite the deep economic recession, R&D spending has held up for oncology diagnostics companies. However, M&A activity has been impacted with the value of deals conducted in 2009 far below the peak year of 2007.Partnerships between diagnostic firms and pharmaceutical firms represents the future of the industry and the number of companion deals has been increasing in the past few years. Virtual colonoscopy – using CT scans to build a picture of the colon – is becoming an increasingly accepted alternative to invasive colonoscopy for colorectal screening in high risk groups and the general population. This presents a sizeable market opportunity. Interesting research is being conducted in both ovarian cancer and for prostate cancer, which could have wide-market implications. Specifically, companies are looking to validate new biomarkers to create more accurate tests.Key questions answered by this reportWhat is the market potential for in vitro diagnostic products?What is the market forecast for oncology diagnostics? What are the key innovations in diagnostic testing and diagnostic imaging?What are the major areas of unmet need in oncology diagnostics?What are the most promising technology areas in oncology diagnostics, and which companies are exploiting these?What will be the key trends impacting the market in the long-term?How can big pharma fully exploit the opportunities in the oncology diagnostics sector? Abbott Diagnostics Affymetrix Beckman Coulter Beckton Dickinson Bio-Rad Gen-Probe Johnson & JohnsonLuminex Nanogen Roche Diagnostics Siemens SysmexFor more information, please visit :http://www.aarkstore.com/reports/Innovations-in-Oncology-Diagnostics-Technological-advances-growth-opportunities-and-future-market-outlook-34066.htmlOr email us at press@aarkstore.com or call +919272852585 Special offer till 31th Dec 2009

Major developments are likely in both the IVD market and in imaging-based modalities, like computed tomography, with the emphasis being upon the personalized medicine approach, where demand will come from physicians, patients and payors – all of whom want more effective treatments and value for money.
This report analyzes the latest innovations in oncology diagnostics and identifies the most exciting new technologies and trends, ranging from body imaging and cytology to molecular diagnostics and pharmacogenomics. The report also identifies the key challenges facing innovative diagnostics companies.
Key Features of this report
•Analysis the latest innovations in diagnostics imaging in the oncology sector, covering Magnetic Resonance Imaging (MRI), x-ray, Computed Tomography (CT), ultrasound, Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT) and Flow Cytometry.•Analyzes the latest innovations in molecular diagnostics and how they impact the diagnostics market. The report covers technology including fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), HPV testing, immunoassays & biomarkers, microarrays and comparative genomic hybridization (CGH).•Analyzes the latest innovations in pharmacogenomics and covers the major applications for familial cancer, breast cancer, colon cancer and lung cancer. Also, the report provides an overview of the regulatory and intellectual property environment for genetic-based tests.•Looks at the key commercial challenges for innovative diagnostics companies, including the impact of the recession, reimbursement, regulatory changes, pharmacoeconomics and the relationship between industry and academia.The report Includes in-depth case studies on the potential technologies available in core areas of un-met need such as ovarian cancer and colorectal cancer.
Key benefits of this report
•Understand the latest innovations in the oncology diagnostics market in the core areas – diagnostic imaging, molecular diagnostics and pharmacogenetics. This includes market information and an analysis of the scientific literature so as to identify what is really innovative.•Identify what the key areas of unmet need are in the oncology diagnostics market and understand which products have the greatest potential over the next decade.•Understand what the greatest challenges are for oncology diagnostics and what the best strategies are for coping with these obstacles. •Understand the competitive landscape and what companies are leading the way in terms of innovation, and what the latest partnerships regarding companion diagnostics.•Business Insights has identified five key areas of innovation in the diagnostics markets, use this to help guide company strategy.
Key findings from this report
Molecular diagnostics and biomarkers are the key drivers of the oncology diagnostics market.
Despite the deep economic recession, R&D spending has held up for oncology diagnostics companies. However, M&A activity has been impacted with the value of deals conducted in 2009 far below the peak year of 2007.
Partnerships between diagnostic firms and pharmaceutical firms represents the future of the industry and the number of companion deals has been increasing in the past few years.
Virtual colonoscopy – using CT scans to build a picture of the colon – is becoming an increasingly accepted alternative to invasive colonoscopy for colorectal screening in high risk groups and the general population. This presents a sizeable market opportunity.
Interesting research is being conducted in both ovarian cancer and for prostate cancer, which could have wide-market implications. Specifically, companies are looking to validate new biomarkers to create more accurate tests.
Key questions answered by this report
What is the market potential for in vitro diagnostic products?What is the market forecast for oncology diagnostics? What are the key innovations in diagnostic testing and diagnostic imaging?What are the major areas of unmet need in oncology diagnostics?What are the most promising technology areas in oncology diagnostics, and which companies are exploiting these?What will be the key trends impacting the market in the long-term?How can big pharma fully exploit the opportunities in the oncology diagnostics sector? 
Abbott Diagnostics Affymetrix Beckman Coulter Beckton Dickinson Bio-Rad Gen-Probe Johnson & JohnsonLuminex Nanogen Roche Diagnostics Siemens Sysmex     Table of Contents : 
Innovations in oncology diagnosticsExecutive summary 10Setting the scene 10Innovations in diagnostic imaging 11Innovations in molecular diagnostics 12Innovations in pharmacogenomics 13Challenges in the oncology diagnostics sector 14Competitive landscape 15Chapter 1 Setting the scene 18Summary 18Introduction 19Cancer facts, current and projected 19History of oncology diagnostics 23Elements of a cancer diagnosis 26Pathology 27Oncology diagnostics market 28Chapter 2 Innovations in diagnostic imaging 34Summary 34Introduction 35Body imaging 35Overview 35X-ray 38Breast cancer 38Computed tomography 40Lung cancer 40Colon cancer 40Others 42Ultrasound 44Magnetic resonance imaging 44Nuclear medicine – PET & SPECT 45Case study 47HYPERImage 47Cytology 47Overview 47Flow cytometry 48Case study 49CellSearch 49Cervical screening 50Cytogenetics 52Chapter 3 Innovations in molecular diagnostics 56Summary 56Introduction 57DNA, genes and chromosomes 59Fluorescence in situ hybridization (FISH) 59PCR and variants 60Case study 61HPV testing 61Immunoassays and biomarkers 62Case study 66Ovarian cancer 66PSA testing 68Other areas of research 70Epigenomics 71Microarrays 72Comparative genomic hybridization (CGH) 73Case study 74Almac 74DiaGenic 74Overview of clinical applications of molecular diagnostics 74BCR-ABL 74LOH 75MSI 75Chapter 4 Innovations in pharmacogenomics 78Summary 78Introduction 79Familial cancer 79Breast cancer 80Colon cancer 81Melanoma 81Case study 82IP challenge 82Response to therapy 83Cytochrome P450 variants 86HER2 overexpression 86The FDA, EMEA and PGx labeling 88Case study 89TheraScreen: KRAS 89BioTheranostics: Breast cancer 89Clarient: Breast cancer 90Marker validation for erlotinib in lung cancer 90Companion diagnostics 91Chapter 5 Challenges in the oncology diagnostics sector 94Summary 94Introduction 95Reimbursement funding 97Educated patients = educated decisions 98Regulation 99Pharmacoeconomics 101Emerging markets 104Partnerships between drug companies & academia 105Research & development 106Mergers & acquisitions 109Chapter 6 Competitive landscape 112Summary 112Introduction 113Abbot Diagnostics 113Affymetrix 114Beckman Coulter 116Becton Dickinson 117Bio-Rad Laboratories 119Gen-Probe 120Johnson & Johnson (J&J) 121Ortho Clinical Diagnostics 121Luminex 121Tm Bioscience 122Nanogen 122Roche Diagnostics 123Siemens Healthcare Diagnostics 126Sysmex 126Future perspectives in the oncology diagnostics market 127Science 127Infrastructure 128Adoption of innovation 130Companion diagnostics 131Chapter 7 Appendix 135Glossary 135Index 138List of FiguresFigure 1.1: Leading sites of new cancer US, 2009 22Figure 1.2: Leading sites of new cancer in developing countries, 2007 23Figure 1.3: Information required by oncologist pre/post diagnosis 27Figure 1.4: Oncology diagnostics forecasts ($bn), 2007-14 30Figure 2.5: Example of the use of 3D tomosynthesis imaging 39Figure 2.6: Number of CT scans in the US, 1995-2008 43Figure 2.7: Women having mammograms (%) in the US, 2004* 45Figure 2.8: Global flow cytometry market forecast ($bn), 2008-14 48Figure 3.9: IV diagnostics market forecast ($bn), 2007-2014) 58Figure 3.10: Use of biomarkers 63Figure 3.11: Obstacles to biomarker development 64Figure 3.12: US 5-year survival (%) for ovarian cancer at time of diagnosis 67Figure 4.13: Myriad: Molecular diagnostics sales ($m), 2005-09 83Figure 4.14: Number of biologics regulated by CDER that have existing PGx information 85Figure 4.15: Herceptin therapy cost ($) per patient relative to HER2 testing 87Figure 5.16: Decline in S&P global sector indices (%), 12 months to December 2008 96Figure 5.17: IV diagnostics risk-based classification 100Figure 5.18: FDA validated biomarkers by therapeutic area, September 2009 102Figure 5.19: Roche Diagnostics regional sales (CHFm), 2008 105Figure 5.20: Leading diagnostic firms increase in R&D spend (%) y-o-y, 2008 107List of TablesTable 1.1: WHO cancer mortality forecasts by region (‘000), 2008-30 21Table 1.2: In vitro diagnostics market forecast ($bn), 2008-14 29Table 2.3: Overview of imaging systems 37Table 2.4: Mortality reduction (%) attributed to FOBT screening, 1985-96 41Table 2.5: Organ radiation data from various clinical studies 44Table 3.6: Extensively investigated cancer biomarkers 65Table 3.7: Market potential for Epigenomics’ cancer specialty tests 72Table 4.8: Absent/incomplete efficacy (%) of drugs by therapeutic class 84Table 5.9: Leading M&A deals in the diagnostics industry ($m), 2009 109Table 6.10: Sales for the leading innovative oncology diagnostics companies ($m), 2006-08 113Table 6.11: Beckman Coulter R&D investment ($m), 2004-08 116Table 6.12: Bio-Rad sales ($bn) 2004-2008 119Table 6.13: Roche Diagnostics sales by division (CHFm), H109 123Table 6.14: Major recent Dx-Rx partnerships 132
  For More information please contact :

http://www.aarkstore.com/reports/Innovations-in-Oncology-Diagnostics-Technological-advances-growth-opportunities-and-future-market-outlook-34066.html

Aarkstore announce a new report  “Innovation in Food and Drinks Packaging: Opportunities in added value and emerging technologies” through its vast collection of market research report. Report Overview…Food and drinks packaging is in a period of rapid change. Growth in the food and drinks packaging markets of developing economies is expected to increase in conjunction with their rising GDP’s, the changing nature of consumer lifestyles and the increased amount of packaged food and drink. Emerging issues such as sustainability and recent increases in raw material prices are also having a significant impact. Understanding trends and issues within the food and drinks packaging market is important due to their significant effect up on manufacturers, retailers, and distributor costs and logistics. ‘Innovation in Food and Drinks Packaging: Opportunities in added value and emerging technologies’ is a report published by Business Insights that provides added value by exploring innovations in food and drinks packaging from both packaging and food and drinks manufacturer perspectives. This report also delivers an overview of competitor activity and an assessment of the strength of trends and market forces moving forward. Key Findings…Glass is the most common material used for new products launched with food safety packaging and this has been relatively stable over the period 2005 to 2008. The next most common material in this category is plastic. Soft drinks (23.5%), took the highest share of food and drinks launched in innovative packaging between 2005 and 2008, closely followed by alcoholic drinks (23.0%). Nanotechnology, interactive packaging, intelligent and active packaging, multi-sensory packaging, and edible packaging are developing innovations that are likely to have an impact on the future of food and drinks packaging. The most commonly used packaging materials in new food and drinks product launches in 2008 in were Plastic (33.2%), glass (11.7%) and cardboard (11.5%). Use this report to…• Understand how regulations are influencing NPD in food and drinks packaging and discover how competitors are responding to new challenges set by these regulations with this new report.• Gain insight into the most up to date packaging technologies including nanotechnology, natural polymers and edible coatings, and evaluate the pros and cons of these new packaging technologies to decide whether these may be appropriate for your organization.• Identify the key trends in food and drinks packaging and the impact that they are expected to have on the food and drinks market in the future.• Enhance your product development strategies with this report’s analysis of green, convenient and supply chain efficient packaged food and drinks product launches by region, category and material. Key issues…Changes to labelling regulations. Recent debate and regulation on food and drinks labeling means detailed information is becoming a requirement in some regions. This is having an impact on the size and design of food and drinks labels and packs in general. The Economic climate. More difficult economic times are one of the factors encouraging consumers to shop in discounters and/or switch from branded items to private labels. In a related effect, the downturn is promoting changes in format and size of packs. The effect of rising prices. The increase in raw material prices has led to some packaging manufacturers passing on price increases to their customers, making cuts within their operating expenses, and in some cases changing the design/format of the packaging material or package itself. Your questions answered…• What major trends are impacting food and drinks packaging development?• How are companies using green packaging materials to lend credibility to their ethical policies?• Who are the top food and drinks packaging manufacturers?• What innovative materials are being used within food and drinks packaging?• Which new technologies, materials and design principles are driving innovation within food and drinks packaging?• What are the key opportunities and challenges within food and drinks packaging? For more information, please visit :http://www.aarkstore.com/reports/Innovation-in-Food-and-Drinks-Packaging-Opportunities-in-added-value-and-emerging-technologies-22034.htmlOr email us at press@aarkstore.com or call +919272852585 Special offer till 31th Dec 2009